Lupus nephritis

This study tests whether combining rituximab with a low dose of mycophenolate mofetil can safely and effectively treat lupus nephritis in children. Lupus nephritis is a serious kidney complication of lupus. The trial enrolls children aged 3 to 18 with active kidney inflammation. …

This early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…

This early-stage trial tests a new treatment called P-CD19CD20-ALLO1, a type of CAR-T cell therapy, for people with severe lupus that hasn't improved with standard treatments. The study will enroll 162 participants and aims to check if the therapy is safe and tolerable. It also l…

This trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that dri…

This early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves…

This early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…

This phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This study tests whether regularly measuring the amount of mycophenolate mofetil in the blood helps more people with lupus kidney disease achieve kidney remission. One hundred adults with active lupus nephritis will be split into two groups: one gets standard dosing, the other ge…

This early study tests a new treatment called ES-NK cells for people with severe lupus nephritis that hasn't responded to standard care. The therapy uses specially grown immune cells to try to control the disease. About 5 to 9 participants will receive different doses to check sa…

This early-stage trial will test whether a personalized immune cell therapy called CAR T-cells is safe for 8 adults with severe lupus that hasn't improved with standard treatments. Participants will receive a single infusion of their own genetically modified cells after a short c…

This study tests a new drug, SIM0278, in 60 adults with active lupus nephritis, a kidney disease caused by lupus. Participants will receive either SIM0278 or a placebo, and researchers will check if the drug helps improve kidney function over 52 weeks. The goal is to see if SIM02…

This early-phase study tests a new treatment called C-CAR168 for people with lupus nephritis that hasn't improved with standard therapies. C-CAR168 is made from a patient's own immune cells, which are modified to target and attack faulty immune cells. The study will enroll 24 adu…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

This early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the dise…

This early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells…

This study looks at whether measuring anti-alpha-actinin antibodies in the blood can help identify active lupus nephritis (kidney inflammation) in people with lupus. Researchers will compare antibody levels with findings from standard kidney biopsies in 96 adults. If the blood te…

This study will observe 50 children (ages 1 month to 18 years) who come to the emergency room with kidney-related symptoms like swelling, blood in urine, or high blood pressure. Researchers want to learn which kidney diseases are most common and how children respond to initial tr…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will check if people with lupus nephritis have low zinc levels and how that relates to kidney function. Researchers will measure zinc, urea, creatinine, and other markers in 75 participants. The goal is to better understand the connection, not to test a treatment.

This study will measure levels of a protein called IL-33 in the blood of 150 people: lupus patients with kidney inflammation, lupus patients without kidney issues, and healthy volunteers. Researchers want to see if higher IL-33 levels are linked to more severe disease, especially…